ERBB2 and breast carcinoma: A study in which 278 HER2‐positive breast cancer cases were counted reported that active Src was positively correlated with trastuzumab resistance and even with shorter survival in patients at early stage with HER2/hormone receptor‐negative tumors treated with trastuzumab 23.